Efficacy of opioid-free anesthesia in reducing postoperative adverse events for thoracoscopic pulmonary surgery: a randomized controlled trial

无阿片类药物麻醉在降低胸腔镜肺部手术后不良事件发生率方面的疗效:一项随机对照试验

阅读:1

Abstract

BACKGROUND: This study compared the effects of opiate-free anesthesia (OFA) using thoracic paravertebral block combined with dexmedetomidine versus traditional anesthesia with sufentanil and remifentanil on postoperative adverse reactions after thoracoscopic lung surgery. METHODS: A prospective, randomized, double-blind trial included 97 patients(49 in OFA group,48 in S group).All received preoperative thoracic paravertebral block.The primary outcome was the incidence of opioid-related adverse reactions (hypoxemia, hypotension, nausea, vomiting, dizziness) at 2,4,6,24,and 48 h postoperatively.Secondary outcomes included intraoperative events, pain scores, opioid consumption, time to first flatus/defecation, and cardiovascular complications. RESULTS: At 2 h postoperatively, hypotension incidence was lower in the OFA group(8.2%vs 33.3%,P = 0.002),with fewer overall adverse reactions (18.4%vs 39.6%,P = 0.018).At 24 h, PONV was 0%in OFA vs. 10.4%in S group(P = 0.027),dizziness was 8.2%vs 22.9%(P = 0.041),and overall adverse reactions were 10.2%vs 27.1%(P = 0.029).OFA had fewer vasopressor applications (P < 0.001), lower 24-hour opioid use (P = 0.033), fewer analgesic pump presses(P = 0.004),and earlier first feeding (9.5 ± 3.8 h vs. 11.4 ± 4.7 h, P = 0.035). CONCLUSION: OFA significantly reduced opioid-related adverse reactions, decreased vasopressor and opioid use, and improved recovery.However, the single-center, small-sample design limits generalizability, and multicenter validation is needed. TRIAL REGISTRATION: This randomized controlled trial was registered on clinicaltrials.gov (ID: NCT04507165; URL: https://clinicaltrials.gov/study/NCT04507165 , 11/08/2020).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。